Clinical Trial: SBRT, Anlotinib and Benmelstobart for RCC.

U.S., March 14 -- ClinicalTrials.gov registry received information related to the study (NCT07470840) titled 'SBRT, Anlotinib and Benmelstobart for RCC.' on March 06.

Brief Summary: To investigate the objective response rate (ORR) of stereotactic body radiotherapy (SBRT) combined with anlotinib and beromuzumab in locally advanced/metastatic renal cell carcinoma.

Study Start Date: Feb. 01, 2027

Study Type: INTERVENTIONAL

Condition: Locally Advanced or Metastatic Renal Cell Carcinoma

Intervention: RADIATION: Stereotactic Body Radiation Therapy (SBRT)

Dose fractionation: 39-48Gy/3f or 40-50Gy/5f, alternative 20-50Gy/5f if OAR dose-limited. Dose adjusted per radiation toxicities during treatment.

DRUG: Anlotinib

Oral anti-angiogenic a...